ES2158200T3 - Conjugado vaccineo. - Google Patents

Conjugado vaccineo.

Info

Publication number
ES2158200T3
ES2158200T3 ES96111909T ES96111909T ES2158200T3 ES 2158200 T3 ES2158200 T3 ES 2158200T3 ES 96111909 T ES96111909 T ES 96111909T ES 96111909 T ES96111909 T ES 96111909T ES 2158200 T3 ES2158200 T3 ES 2158200T3
Authority
ES
Spain
Prior art keywords
virus
vaccine conjugate
antibody
subjects
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96111909T
Other languages
English (en)
Inventor
Craig E Whitfill
Tommy L Fredericksen
Julius K Tyczkowski
James Paul Thaxton Jr
John A Dr Thoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas at Fayetteville
Original Assignee
University of Arkansas at Fayetteville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas at Fayetteville filed Critical University of Arkansas at Fayetteville
Application granted granted Critical
Publication of ES2158200T3 publication Critical patent/ES2158200T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METODO PARA PRODUCIR INMUNIDAD ACTIVA CONTRA UNA ENFERMEDAD VIRAL EN SUJETOS ANIMALES QUE SUPONE LA ADMINISTRACION A ESTOS SUJETOS DE UN CONJUGADO DE VACUNA QUE CONSISTE ESENCIALMENTE EN UN VIRUS VIVO Y UN FACTOR DE NEUTRALIZACION UNIDO AL VIRUS VIVO. EL FACTOR DE NEUTRALIZACION SE SELECCIONA A PARTIR DEL GRUPO CONSISTENTE EN ANTICUERPOS Y FRAGMENTOS DE ANTICUERPO. EL VIRUS VIVO ES UNO CAPAZ DE PRODUCIR LA ENFERMEDAD EN EL SUJETO, MIENTRAS QUE EL ANTICUERPO O FRAGMENTO DE ANTICUERPO TIENE CAPACIDAD PARA NEUTRALIZAR EL VIRUS VIVO.
ES96111909T 1989-10-02 1990-10-01 Conjugado vaccineo. Expired - Lifetime ES2158200T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41603589A 1989-10-02 1989-10-02
US48067890A 1990-02-15 1990-02-15
US58685990A 1990-09-24 1990-09-24

Publications (1)

Publication Number Publication Date
ES2158200T3 true ES2158200T3 (es) 2001-09-01

Family

ID=27411077

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90917281T Expired - Lifetime ES2102368T3 (es) 1989-10-02 1990-10-01 Conjugado de vacuna para el tratamiento de las enfermedades de las aves.
ES96111909T Expired - Lifetime ES2158200T3 (es) 1989-10-02 1990-10-01 Conjugado vaccineo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES90917281T Expired - Lifetime ES2102368T3 (es) 1989-10-02 1990-10-01 Conjugado de vacuna para el tratamiento de las enfermedades de las aves.

Country Status (11)

Country Link
US (4) US5397569A (es)
EP (2) EP0755684B1 (es)
AT (2) ATE200735T1 (es)
AU (2) AU641958B2 (es)
BR (1) BR9007702A (es)
CA (1) CA2066661C (es)
DE (2) DE69030383T2 (es)
DK (2) DK0495008T3 (es)
ES (2) ES2102368T3 (es)
IL (1) IL95867A (es)
WO (1) WO1991004749A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JPH07206705A (ja) * 1993-11-03 1995-08-08 American Cyanamid Co 生インオボ（ｉｎ ｏｖｏ）ワクチン
US5807551A (en) * 1996-04-01 1998-09-15 Iowa State University Research Foundation, Inc. Method to provide artificial passive immunity in birds
PL332540A1 (en) 1996-09-30 1999-09-13 Embrex Method of inducing active immunity using a vaccine conjugate
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
HUP0202537A3 (en) 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1161953A3 (en) * 2000-06-09 2004-02-04 Akzo Nobel N.V. IBDV strain for in OVO administration
ZA200104596B (en) * 2000-06-09 2001-12-06 Akzo Nobel Nv IBDV strain for in ovo administration.
US7037506B2 (en) 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US7029681B2 (en) 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
EP1546358A4 (en) 2002-03-22 2006-06-07 Zymogenetics Inc ANTI-IL-TIF ANTIBODIES AND METHOD FOR USE ON INFLAMMATION
US6729265B2 (en) * 2002-06-27 2004-05-04 Arkion Life Sciences Llc Supplemented antibody feed to enter the circulating system of newborns
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
EP2164511A1 (en) * 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
US10335484B2 (en) 2013-01-08 2019-07-02 Humabs Biomed Sa Methods of generating robust passive and active immune responses
CN103341164B (zh) * 2013-07-19 2015-06-24 天津瑞普生物技术股份有限公司 一种鸡传染性法氏囊病抗原抗体复合物、制剂及制备方法
BR112022004488A2 (pt) 2019-09-11 2022-05-31 Zoetis Services Llc Herpesvírus recombinante de vetores de peru que expressam antígenos de patógenos aviários e seus usos

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2518978A (en) * 1946-09-12 1950-08-15 American Cyanamid Co Hog cholera vaccine
DE1041214B (de) * 1957-03-11 1958-10-16 Dr Med Karl Theurer Verfahren zur Herstellung von Impfstoffen gegen Viruserkrankungen
US3846543A (en) * 1963-01-02 1974-11-05 Monsanto Co Process for the separation of virus from non-viral proteins
US3326767A (en) * 1966-03-21 1967-06-20 Abbott Lab Avian leukosis treatment with inactivated rous sarcoma virus
US3651213A (en) * 1969-05-29 1972-03-21 Monsanto Co Method for the immunization of a living animal body against viral disease
US3853467A (en) * 1973-08-15 1974-12-10 Gen Electric Method and apparatus for immunological detection of biological particles
CA1039649A (en) * 1973-08-30 1978-10-03 General Electric Company Method of forming multilayer immunologically complexed films
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
EP0073856A1 (en) * 1981-08-28 1983-03-16 Gist-Brocades N.V. Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4493825A (en) * 1982-10-05 1985-01-15 Iowa State University Research Foundation Purified and antigenically selective vaccines for domestic animals
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US4956452A (en) * 1987-06-14 1990-09-11 The University Of Maryland Monoclonal antibody which neutralizes multiple strains of infectious bursal disease virus
US4867975A (en) * 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors

Also Published As

Publication number Publication date
WO1991004749A1 (en) 1991-04-18
CA2066661A1 (en) 1991-04-03
US6299874B1 (en) 2001-10-09
DK0495008T3 (da) 1997-10-13
US6136319A (en) 2000-10-24
ATE150976T1 (de) 1997-04-15
DE69030383D1 (de) 1997-05-07
ES2102368T3 (es) 1997-08-01
EP0755684B1 (en) 2001-04-25
EP0495008A1 (en) 1992-07-22
DE69033728D1 (de) 2001-05-31
IL95867A0 (es) 1991-07-18
CA2066661C (en) 2001-05-08
DK0755684T3 (da) 2001-08-20
EP0495008A4 (en) 1993-05-05
ATE200735T1 (de) 2001-05-15
AU6714290A (en) 1991-04-28
EP0755684A1 (en) 1997-01-29
DE69033728T2 (de) 2001-11-22
BR9007702A (pt) 1992-08-18
US5871748A (en) 1999-02-16
IL95867A (en) 1994-10-07
AU641958B2 (en) 1993-10-07
DE69030383T2 (de) 1997-10-23
US5397569A (en) 1995-03-14
EP0495008B1 (en) 1997-04-02
AU6755990A (en) 1991-04-28

Similar Documents

Publication Publication Date Title
ES2065303T5 (es) Procedimiento de diagnosis y vacuna especifica.
ES2102368T3 (es) Conjugado de vacuna para el tratamiento de las enfermedades de las aves.
US5008116A (en) Immunostimulatory microsphere
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ID21338A (id) Metoda untuk menghasilkan kekebalan aktif dengan vaksin gabungan
RU2010129538A (ru) Коньюгаты ngf и их применение
ATE174223T1 (de) Verwendung von oncostatin m zur suppression von mhc antigenen
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
BR0014666A (pt) Vacina
WO2000073432A3 (en) Activation of dendritic cells to enhance immunity
NO890565L (no) Forhindring og behandling av retroviral sykdom.
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
CN1339320A (zh) 一种艾滋病疫苗及其制备方法与应用
ATE332920T1 (de) Nukleinsäureimpfstoff bestehend aus einem fusionsprotein, dass eine adjuvanssequenz von einem planzenvirushüllprotein aufweist
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
FR2608926B1 (fr) Antigene de babesia divergens, procede pour le produire et vaccin le contenant
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
RU96113001A (ru) Способ определения иммуногенной активности противоящурных вакцин
FI883765L (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.
RU2012106224A (ru) СПОСОБ ПОЛУЧЕНИЯ ВАКЦИНЫ НА ОСНОВЕ ЖИВЫХ ЛИЧИНОК НЕМАТОД РОДА Trichinella Railliet (1895) ДЛЯ ИММУНИЗАЦИИ ЖИВОТНЫХ И ЧЕЛОВЕКА, ПРИМЕНЕНИЕ МОЛОКА ЖИВОТНОГО, ИММУНИЗИРОВАННОГО ЭТОЙ ВАКЦИНОЙ, В КАЧЕСТВЕ СРЕДСТВА ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ИММУННОЙ СИСТЕМЫ, СПОСОБ ПОЛУЧЕНИЯ СЫВОРОТКИ ИЗ КРОВИ ИММУНИЗИРОВАННЫХ ЖИВОТНЫХ И СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ИММУННОЙ СИСТЕМЫ С ПОМОЩЬЮ ТАКОЙ СЫВОРОТКИ
MX171572B (es) Substancia que contiene anticuerpo especifico a partir de huevos y metodo de produccion y uso de la misma
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
SU303075A1 (ru) Способ устранения антикомплементарной активности антигенов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 755684

Country of ref document: ES